CIVAX | RERAX | CIVAX / RERAX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 5 years | 23 years | - |
Gain YTD | 4.299 | 3.168 | 136% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250 | 250 | 100% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 2.04B | 131B | 2% |
Annual Yield % from dividends | 1.10 | 0.91 | 120% |
Returns for 1 year | 6.39 | 4.26 | 150% |
Returns for 3 years | 3.54 | -8.95 | -39% |
Returns for 5 years | 22.63 | 2.29 | 989% |
Returns for 10 years | N/A | 18.36 | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
MSAQX | 22.37 | 0.13 | +0.58% |
Morgan Stanley Inst Asia Opp I | |||
MSEQX | 61.68 | 0.23 | +0.37% |
Morgan Stanley Inst Growth I | |||
WOOQX | 19.14 | -0.19 | -0.98% |
JPMorgan SMID Cap Equity R4 | |||
EEMGX | 8.09 | -0.09 | -1.10% |
MFS Emerging Markets Equity Research R4 | |||
NINLX | 22.30 | -0.31 | -1.37% |
Neuberger Berman Intrinsic Value I |